Barriers to cardiovascular risk prevention and management in Germany - An analysis of the EURIKA study

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 177-186

  Schmieder, Roland E ^a   Goebel, Matthias ^b   Bramlage, Peter ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b ASTRAZENECA   (United Kingdom)

^c Institut fur Pharmakologie und Praventive Medizin   (Germany)

Author keywords

Cardiovascular risk factor; Primary care

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GERMANY; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; RISK ASSESSMENT; AGE; AGED; ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; INTERDISCIPLINARY COMMUNICATION; MIDDLE AGED; MULTICENTER STUDY; PRIMARY PREVENTION; RISK; RISK FACTOR; STATISTICS; WORKLOAD;

ADULT; AGE FACTORS; AGED; ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; QUALITY INDICATORS, HEALTH CARE; RISK ASSESSMENT; RISK FACTORS; WORKLOAD;

EID: 84863204582     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S29915     Document Type: Article

References (45)

1. Graham I, Atar D, Borch-Johnsen K, et al; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDF-Europe); European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-S113
2. Mancia G, De Backer G, Dominiczak A, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension, The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12): 1462-1536
3. National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421
4. Bhatt DL, Steg PG, Ohman EM, et al. REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2): 180-189
5. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-137
6. De Backer G, Ambrosioni E, Borch-Johnsen K, et al; Third Joint Task Force of the European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24(17):1601-1610
7. Conroy RM, Pyorala K, Fitzgerald AP, et al; SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003
8. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract. 2002;19(6):596-604
9. Graham IM, Stewart M, Hertog MG; Cardiovascular Round Table Task Force. Factors impeding the implementation of cardiovascular prevention guidelines: findings from a survey conducted by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil. 2006;13(5):839-845
10. Erhardt LR, Hobbs FD. A global survey of physicians' perceptions on cholesterol management: the From The Heart study. Int J Clin Pract. 2007;61(7):1078-1085
11. Bramlage P, Thoenes M, Kirch W, Lenfant C. Clinical practice and recent recommendations in hypertension management - reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin. 2007;23(4):783-791
12. Celentano A, Panico S, Palmieri V, et al. Citizens and family doctors facing awareness and management of traditional cardiovascular risk factors: results from the Global Cardiovascular Risk Reduction Project (Help Your Heart Stay Young Study). Nutr Metab Cardiovasc Dis. 2003; 13(4):211-217
13. Rodriguez-Artalejo F, Guallar E, Borghi C, et al; EURIKA Investigators. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health. 2010;10:382
14. Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011; 32(17):2143-2152
15. Dallongeville J, Banegas JR, Tubach F, et al. Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Cardiovasc Prev Rehabil. 2011. Epub Apr 18
16. Guallar E, Banegas JR, Blasco-Colmenares E, et al. Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. BMC Public Health. 2011;11:704
17. Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. Int J Cardiol. 2011. Epub Nov 4
18. OneKey database. Bensheim: Cegedim Deutschland GmbH; nd. Available from http://crm.cegedim.com/country/germany/En/DataOptimization/OneKey/Pages/default.aspx. Accessed March 8, 2012
19. Stark RG, Schunk MV, Meisinger C, Rathmann W, Leidl R, Holle R; HORA Study Group. Medical care of type 2 diabetes in German disease management programs: a population-based evaluation. Diabetes Metab Res Rev. 2011;27(4);383-391
20. Bestehorn K, Jannowitz C, Karmann B, Pittrow D, Kirch W. Characteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. BMC Public Health. 2009;9:280
21. Prugger C, Heuschmann PU, Keil U. Epidemiology of hypertension in Germany and worldwide. Herz. 2006;31(4):287-293. German.
22. Wittchen HU, Krause P, Hofler M, et al. Aim, design and methods of the "Hypertension and diabetes screening and awareness" - (HYDRA) study. Fortschritte der Medizin. 2003;121 Suppl 1:2-11. German.
23. Johansson H, Stenlund H, Lundstrom L, Weinehall L. Reorientation to more health promotion in health services - a study of barriers and possibilities from the perspective of health professionals. J Multidiscip Healthc. 2010;3:213-224
24. Wensing M, Van den Hombergh P, Van Doremalen J, Grol R, Szecsenyi J. General practitioners' workload associated to practice size rather than chronic care organisation. Health Policy. 2009;89(1):124-129
25. Cullen W, Grogan L, O'Connor E, Bury G. "Why are we working so hard?" A cross-sectional survey of factors influencing GP workload in the Eastern Regional Health Authority area. Ir Med J. 2002;95(7): 209-212, 214
26. Whalley D, Bojke C, Gravelle H, Sibbald B. GP job satisfaction in view of contract reform: a national survey. Br J Gen Pract. 2006;56(523): 87-92
27. Wensing M, van den Hombergh P, Akkermans R, van Doremalen J, Grol R. Physician workload in primary care: what is the optimal size of practices? A cross-sectional study. Health Policy. 2006;77(3): 260-267
28. Fernandez A, Grumbach K, Vranizan K, Osmond DH, Bindman AB. Primary care physicians' experience with disease management programs. J Gen Intern Med. 2001;16(3):163-167
29. Miksch A, Laux G, Ose D, et al. Is there a survival benefit within a German primary care-based disease management program? Am J Manag Care. 2010;16(1):49-54
30. Hagemeister J, Schneider CA, Barabas S, et al. Hypertension guidelines and their limitations - the impact of physicians' compliance as evaluated by guideline awareness. J Hypertens. 2001;19(11):2079-2086
31. Baberg HT, Yazar A, Brechmann T, et al. Health care quality: medication and prevention in patients with and without coronary heart disease. Med Klin (Munich). 2004;99(1):1-6. German.
32. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care. 2007;30(5): 1292-1293
33. McEwan P, Williams JE, Griffiths JD, et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med. 2004;21(4):318-323
34. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med. 2005;22(5): 554-562
35. Yang X, So WY, Kong AP, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol. 2008;101(5):596-601
36. Ulmer H, Kollerits B, Kelleher C, Diem G, Concin H. Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44,649 Austrian men and women. Eur J Cardiovasc Prev Rehabil. 2005;12(5):433-441
37. Bastuji-Garin S, Deverly A, Moyse D, et al. Intervention as a Goal in Hypertension Treatment Study Group. The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens. 2002;20(10):1973-1980
38. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327(7426):1267
39. Sharma AM, Wittchen HU, Kirch W, et al; HYDRA Study Group. High prevalence and poor control of hypertension in primary care: crosssectional study. J Hypertens. 2004;22(3):479-486
40. Bohler S, Glaesmer H, Pittrow D, et al. Diabetes and cardiovascular risk evaluation and management in primary care: progress and unresolved issues - rationale for a nationwide primary care project in Germany. Exp Clin Endocrinol Diabetes. 2004;112(4):157-170
41. Hauner H, Bramlage P, Losch C, et al. Prevalence of obesity in primary care using different anthropometric measures - results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). BMC Public Health. 2008;8:282
42. Stewart D, Cunningham IT, Hansford D, John D, McCaig D, McLay J. General practitioners' views and experiences of over-the-counter simvastatin in Scotland. Br J Clin Pharmacol. 2010;70(3):356-359
43. Filion KB, Delaney JA, Brophy JM, Ernst P, Suissa S. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2007;16(1):1-4
44. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - a review. Cardiovasc Diabetol. 2009;8:18
45. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Insitute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289(19):2560-2572.